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tent-assisted coil (SAC) embolization is an effective endovascular treatment modality for intracranial wide-necked, fusiform, or dissecting aneurysms. Use of a stent facilitates aneurysm coiling and yields a more durable aneurysm obliteration compared with ABBREVIATIONS: ADP, adenosine diphosphate; CI, confidence interval; CPG, clopidogrel; DM, diabetes mellitus; HDL, high-density lipoprotein; LDL, lowdensity lipoprotein; LVIS, low-profile visualized intraluminal support; OR, odds ratio; PLATO, study of platelet inhibition and patient outcomes; PRU, P2Y12 reaction unit; PSG, prasugrel; SAC, stent-assisted coil; UIAs, unruptured intracranial aneurysms Neurosurgery Speaks! Audio abstracts available for this article at www.neurosurgery-online.com. coil embolization alone. 1, 2 However, the use of stents increases thromboembolic events during coil embolization and can result in more frequent ischemic neurological sequelae. [3] [4] [5] Prior to the embolization procedure, most practitioners now administer 2 antiplatelet agents, clopidogrel (CPG) and aspirin, to reduce the risk of ischemic adverse events. Notably, poor response to CPG is one of the risk factors of ischemic complications. 1, [6] [7] [8] [9] [10] Recently, a third-generation thienopyridine, prasugrel (PSG), was introduced, and a number of interventionists have begun to use it as a prophylactic antiplatelet therapy for the endovascular treatment of intracranial aneurysms. after oral administration. 14, 15 Furthermore, the majority of metabolites of PSG are active. As a result, PSG provides a more rapid and consistent inhibition of ADP-induced platelet aggregation regardless of age, diabetes, smoking, or renal impairment. Although some previous studies have reported clinical outcomes of preprocedural administration of PSG in coil embolization of cerebral aneurysms, 11, [16] [17] [18] its safety and effectiveness in preventing thromboembolism related to SAC remains unclear. In this study, we performed a retrospective study to determine the safety and effectiveness of low-dose PSG in comparison with CPG as a prophylactic antiplatelet medication for patients undergoing SAC of unruptured intracranial aneurysms.
METHODS

Study Population and Data Collection
Between November 2014 and March 2017, coil embolization was performed in 928 patients with 1094 intracranial aneurysms; of these, 304 patients with 329 aneurysms (30.1%) underwent SAC at our institution. Among the 329 aneurysms, 15 aneurysms (in 14 patients) treated at the time of rupture and 3 aneurysms (3 patients) lacking platelet function test were excluded from the study; 297 patients with 311 aneurysms were ultimately included in this analysis. Multiple patient variables were retrieved from the medical records, including age, sex, body weight, body mass index, hypertension, diabetes mellitus (DM), hyperlipidemia, smoking, alcohol use, and history of antiplatelet therapy. Angiographic and laboratory variables included were the size of the aneurysm, depth-to-neck ratio, aneurysmal location, type of stent, dissecting aneurysm, platelet count, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride levels.
All patients underwent cerebral angiography and rotational angiography with 3-dimensional image reconstruction using Integris V (Philips Medical Systems, Best, The Netherlands), Allura Clarity (Philips Medical Systems), or Innova IGS 630 (GE Healthcare, Wauwatosa, Wisconsin) to evaluate precise aneurysmal configurations and determine proper therapeutic plans. The maximal diameters of aneurysms and the depth and neck dimension were measured on proper working projection from the 3-dimensional reconstructed angiographic images. The study protocol was conducted according to the principles outlined in the Declaration of Helsinki and approved by the institutional review board of our hospital.
Periprocedural Antiplatelet Medication and Platelet Activity Measurement
The patients were classified into 2 groups: the CPG group and the low-dose PSG group. Antipletelet regimen was decided by the referring physicians. Patients who were already taking CPG or PSG continued the original medication. In both groups, whole blood was obtained 6 h after loading with an antiplatelet medication for use in the VerifyNow assay (Accumetrics, San Diego, California). P2Y 12 reaction unit (PRU) and percentage inhibition values were measured to evaluate platelet reactivity. A poor responder was defined by a PRU value greater than 285. The PRU of 285 as the cutoff value of response to thienopyridine medication is based on a previous study. 6 In this study, the third (PRU value of 285-332) and fourth quartile group (PRU value more than 332) of patients demonstrated higher incidence of procedure-related thromboembolic and all adverse events. In the CPG group, patients were given dual antiplatelet medications (aspirin and CPG with a loading dose 300 mg for each) on the day prior to the neurointerventional procedure; an additional 75 mg of CPG and 100 mg aspirin were given the morning of the procedure. For the poor responders, cilostazol (200 mg) was added. In the PSG group, 20 mg of PSG was given the day prior to the procedure, and an additional 5 mg of PSG was given the morning of the procedure. An additional 10 mg of PSG was given to poor responders. Maintenance antiplatelet therapy was recommended for at least 3 months after the procedure, followed by a life-long aspirin regimen.
Endovascular Procedure and Procedural Complications
Therapeutic alternatives were formulated by multidisciplinary neurosurgical and neuro-interventional teams and discussed with patients and their family members; informed consent was obtained in each case. Most procedures were performed under general anesthesia. Intravenous unfractionated heparin (3000 IU) was administered after femoral sheath placement followed by an intermittent bolus (1000 IU) every hour. The activated clotting time was monitored every hour, and heparin was titrated to maintain it 250 to 300 s.
Hemorrhagic complications were diagnosed when there was direct visualization of a device outside of the aneurysm lumen and extravasation of contrast during the procedure or if there was intracranial bleeding within 60 d of the procedure. Thromboembolic complications were diagnosed when there was a luminal filling defect, stagnation of contrast in a vessel, or nonvisualization of a distal artery. In cases with procedural thromboembolism, an infusion of tirofiban or heparin was maintained up to 12 h after the embolization procedure. Clinically recognized ischemic deficits with a treatment-related vascular territory infarction were also included as thromboembolic complications. All patients were instructed to visit the emergency center or contact the neurointerventional team by telephone when any neurological symptom occurred.
Statistical Analysis
Continuous variables were presented as mean ± standard deviation. Chi-square or Fisher exact and Student t test were used to analyze categorical and continuous variables. Univariate analysis of parameters impacting thromboembolism was conducted via binary logistic regression using variables with P values <.20 in a multivariable model. All results from the logistic regression model were reported as odds ratio (OR), 95% confidence interval (95% CI), and P value. A 2-tailed P value < .05 was considered statistically significant. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS, Version 22, IBM, Armonk, New York).
RESULTS
Enrolled Patients and Aneurysms
The baseline characteristics of patients, laboratory data, and treated aneurysms are shown in Table 1 . Baseline characteristics of the PSG and CPG groups were well balanced except for DM. The types of stent used during coil embolization did not differ significantly between the 2 groups (P = .19). In the CPG group, the majority of patients (n = 63; 70.0%) received dual antiplatelet medications, followed by triple antiplatelet medication in 22 patients (24.4%), and single antiplatelet medication with CPG in 5 patients (5.6%). In the PSG group, all of the patients received only PSG; 203 patients (98.1%) received a loading dose of 20 mg (Figure) . The incidence of poor responders to antiplatelet medication was lower in the PSG group (2.4% vs 26.7%; P < .001).
Thromboembolic complications developed less frequently in the PSG group (0.9% vs 6.4%; P = .01; Table 4 ), and the details of the patients are shown in Table 5 . The incidence of hemorrhagic complications was not higher in the PSG group (0.5% vs 2.2%; P = .22). In the PSG group, 1 patient suffered from aneurysm rupture during the procedure. Hemorrhagic complications occurred in 2 patients in the CPG group. One had an aneurysm rupture during the procedure and the other suffered a right temporal hemorrhage 1 month after the SAC. All 3 patients with hemorrhagic complications recovered with no neurological sequelae.
TABLE 2. Preprocedural and Maintenance Antiplatelet Medication
Preprocedural medication
Maintenance medication a n 
TABLE 4. Comparison of Procedure-Related Adverse Events
Complication PSG group (%) CPG group (%) P-value
Hemorrhagic complication 1 (0.5%) 2 (2.2%) .218 Thromboembolism 2 (0.9%) 6 (6.4%) .011 
FIGURE. Distribution of measured responses to antiplatelet therapies. A, Histogram of PRU values in the PSG and CPG groups. B, Histogram of percentage inhibition values in the PSG and CPG groups.
Risk Factor Analysis of Procedure-Related Thromboembolism
The risk factors for SAC-related thromboembolism in patients with unruptured intracranial aneurysms (UIAs) were evaluated using the following variables: age (>65 yr), gender, body weight (>60 kg), CPG antiplatelet premedication, hypertension, DM, hyperlipidemia, smoking, alcohol, hematocrit (>38%), platelet count (>227 000/μL), HDL cholesterol (<40 mg/dL), LDL cholesterol (>130 mg/dL), poor response to thienopyridine therapy (PRU > 285), prior antiplatelet therapy, posterior circulation aneurysm, dissecting aneurysm, maximum aneurysm size (>7 mm), aneurysm depth-to-neck ratio (>1.5), Lowprofile Visualized Intraluminal Support (LVIS) stent, and repeat aneurysm treatment (Table 6 ). In the univariate analysis, CPG antiplatelet premedication and poor response to antiplatelet therapy showed statistical significance. On the multivariate logistic regression analysis, CPG antiplatelet premedication was found to be the sole significant risk factor of thromboembolic complications in this cohort of patients undergoing SAC embolization (OR = 13.200; 95% CI 1.476-118.025; P = .021).
DISCUSSION
In this study, low-dose PSG medication showed a remarkable reduction in the frequency of procedure-related thromboembolism compared with tailored CPG-based therapy among patients with UIAs treated with SAC embolization (PSG group vs CPG group, 0.9% vs 6.4%; P = .01). This result correlated well with the laboratory responsiveness, namely, the lower PRU and higher percentage inhibition values in the low-dose PSG group. Moreover, the rate of hemorrhagic complications did not increase in the PSG group.
The effectiveness of PSG in preventing thromboembolic complication of vascular procedures was first demonstrated in coronary disease patients. 19, 20 PSG showed a more rapid and consistent platelet inhibition than CPG, and the patients who received PSG had a lower rate of ischemic complications including stent thrombosis compared with those who received CPG. Despite the more potent antiplatelet effects of PSG, the higher rate of hemorrhagic complications has been a serious obstacle to its widespread use in neurovascular procedures. The use of PSG for neurointerventional procedures was first introduced in a patient who developed intracranial stent thrombosis in spite of taking dual antiplatelet premedication with aspirin and CPG in 2011. 12 The concern for the hemorrhage was consolidated with the report of Akbari et al. 11 Akbari et al 11 reported an increased risk of hemorrhagic complications in the patients who received a 60 mg loading dose of PSG and a 10 mg maintenance dose after the procedure compared with those who received aspirin and CPG at least 7 d prior to the procedure (19.4% vs 3.6%, P = .02). Moreover, the incidence of thromboembolic complications was not different between the 2 groups. Jones et al 13 reported that reducing the PSG maintenance dose from 10 to 5 mg did not increase the risk of severe bleeding in 2 patients treated with pipeline embolization devices. 13 Stetler et al 17 also presented 16 patients who underwent neurointerventional procedures with PSG antiplatelet medication. Among these 16 patients, 13 were CPG-nonresponders (<20% platelet P2Y12 receptor inhibition) and 3 were allergic to CPG. All 16 patients received a PSG loading dose of 40 mg and a maintenance dose of 5 to 10 mg postoperatively and showed neither ischemic nor intracranial hemorrhagic complications. Ha et al 18 presented a rather large study including 98 patients premedicated with 20 or 30 mg PSG and 96 patients with CPG. The PRU values were significantly lower (125.7 ± 79.4 vs 242.7 ± 69.8; P < .001) and the percentage inhibition values were significantly higher (60.2 ± 24.7% vs 22.1% ± 19.7%; P < .001) in the PSG group. 18 There were no thromboembolic events and only 1 hemorrhagic complication involving procedural bleeding in each group. The study showed a more effective and consistent platelet inhibition by PSG in neurovascular procedures without an increase in hemorrhagic complications. Sedat et al 16 compared PSG (n = 100) with CPG (n = 100) in patients treated with SAC embolization. The rates of hemorrhagic complications and thromboembolic events in the 2 groups were comparable, and the clinical outcomes on day 30 were excellent in the PSG group. Sedat et al 16 reported that the chance of thromboembolic events did not differ significantly between the CPG group and the PSG group, while thromboembolic events occurred less frequently in the PSG group (0.9% vs 6.4%; P = .01) in our series. Actually, the rate of thromboembolism of the PSG group (12%) was lower than that of the CPG group (17%) in their series, although not in a statistical way. Furthermore, there was neither proximal artery occlusion nor stent thrombosis in their PSG cohort, which was in stark contrast with the CPG group. Unfortunately, Sedat et al 16 did not present on the functional test data such as VerifyNow assay or genotyping data like CYP2C19 alleles. Thus, the laboratory effectiveness of their antiplatelet regimen was not confirmed. The ethnic difference might be a cause for the data divergence. [21] [22] [23] In this study, we compared PRU and percentage inhibition values between the PSG group (20 mg PSG) and the CPG group. Similar to the previous study, PRU values were significantly lower (132.3 ± 76.9% vs 238.1 ± 69.1%, P < .001), and percentage inhibition values were significantly higher (54.0 ± 26.0 vs 20.8 ± 18.6, P < .001) in the PSG group. Thanks to the effective inhibition of platelet function in the PSG group, the rate of thromboembolic complications decreased significantly in the PSG group (0.9% vs 6.4%; P = .01) without a significant increase in the rate of hemorrhagic complications (0.5% vs 2.2%; P = .22). Among 8 patients with thromboembolic complication, 7 were treated with LVIS Jr or LVIS stent. However, use of LVIS stent was not a significant risk factor of the thromboembolism (LVIS vs others, 3.6% vs 1.5%; P = .279). All patients with hemorrhage recovered with no neurological sequelae. In the multivariate analysis, the use of CPG antiplatelet premedication was the only significant independent risk factor associated with thromboembolic complications in patients undergoing SAC (OR = 13.200; 95% CI 1.476-118.025; P = .021). In the CPG group, we administrated dual antiplatelet medication with aspirin, and poor responders also received 200 mg cilostazol to decrease thromboembolic events. 6, 24 Nevertheless, low-dose PSG showed more effective prevention than tailored CPG premedication.
19
Ticagrelor might be an alternative prophylactic medication in patients undergoing neuroendovascular procedures. 25 Hanel et al 25 administerd ticagrelor (loading dose of 180 mg) in 18 CPG-nonresponsive patients (defines as percentage inhibition less than 30%). After the additional medication, 17 of 18 patients showed percentage inhibition more than 60%, and there were no adverse events related to ticagrelor but with no detailed description of other unrelated events. As the authors noted, the need for twice a day administration is a potential drawback, which may compromise patients' compliance. In addition, serious cardiac side effects including ventricular pause, atrioventricular block, and atrial fibrillation have been reported since the Study of Platelet Inhibition and Patient Outcomes (PLATO) trial. [26] [27] [28] There are black box warnings on the bleeding risk of PSG, which states that significant and sometimes fatal bleeding may occur and it is contraindicated in patients with active bleeding or history of stroke and transient ischemic attack. We believe that the warning need to be kept in mind, and our results demonstrate that low-dose PSG regimen as monotherapy can be safely applied in patients undergoing stent-assisted treatment for unruptured aneurysms without further risk of bleeding.
Limitations
Our study has limitations due to its retrospective design and because the patients were not randomly assigned. The optimal dose of PSG for effectiveness and safety was also not evaluated. In order to generate clinical guidelines, a prospective randomized controlled study is needed to clarify the effectiveness and safety of PSG antiplatelet premedication in patients undergoing SAC embolization.
CONCLUSION
Use of low-dose PSG as an antiplatelet premedication was effective and safe for patients undergoing SAC embolization of UIAs. With lower PRU and higher percentage inhibition values in the PSG group, there was a remarkable reduction in the rate of thromboembolic complications without an increase in the rate of hemorrhagic complications.
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